Sun, Apr 20, 2014, 6:30 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • johnkelly6914 johnkelly6914 Aug 26, 2011 8:03 PM Flag

    S&P maintains BUY

    S&P MAINTAINS BUY OPINION ON SHARES OF NEUROCRINE BIOSCIENCES
    (Standard & Poor's)
    We continue to expect NBIX's partnered elagolix to start Phase III study for endometriosis by late '11. We also see its VMAT2 program for tardive dyskinesia advancing to Phase IIb study in '12. While we view NBIX as poised to limit cash burn with elagolix milestones, we expect the shares to remain volatile, given recent pressure on small cap biotechs. Looking ahead, the Capital IQ earnings consensus is $0.63 for 2011 and $0.09 for 2012, vs. our prior estimate of $0.67 and $0.17, respectively. On revised risk profile, we trim our NPV-based target price by $1 to $10.

 
NBIX
13.45-0.39(-2.82%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST